EX-99.1

2 aspi-ex99_1.htm

EX-99.1

EX-99.1

EXHIBIT 99.1

ASP Isotopes Issues Letter to Shareholders

DALLAS, August 4, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes”, “ASPI” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today released the following letter to shareholders from its Executive Chairman and Chief Executive Officer, Paul Mann.

Dear Fellow Shareholder,

As we prepare to announce financial results for the second quarter of 2026, I wanted to take this opportunity to update you on the developments taking place at ASP Isotopes Inc.

All of our business units are making considerable progress, group revenues are increasing, and three of our business units appear at an inflection point and are expected to make substantial contributions to achieving profitability in the near term:

• During 1H 2026, our global PET Labs group demonstrated organic revenue growth of over 50% as compared to 1H 2025. We forecast that PET Labs is on track to deliver FY 2026 revenues of approximately $14 million, up from $6 million in 2025. We believe our projected growth is on track to deliver an annual $50-100m of EBITDA in 2031.1

• We expect to commence helium production at Renergen prior to September 30, 2026. At current expected prices, annualized forecasted helium and LNG revenues are expected to be approximately $27 million after the expected completion of Phase 1.2 In the current geopolitical environment where approximately 50% of global helium supply is estimated to be currently offline3, the world is desperately seeking an additional supplier of helium in a geopolitically neutral location, and we are prioritizing helium production to meet these demands.

• Our Silicon-28 and Ytterbium-176 enrichment facilities are in the final stages of commercial production, and we expect to ship initial product during 2H 2026. While the delays in our stable isotope division have been frustrating, these delays are attributable primarily to performance issues with certain equipment provided by our former OEM suppliers, not performance issues with our ASP technology. Our core enrichment technology continues to perform in line with our theoretical models,

1 See footnote 4 below.

2 We anticipate that Phase 1 will reach a planned production capacity of 2,500GJ of LNG and 250kg of LHe per day.

3 Source: Around half of helium supply still unavailable in “struggling market” | Specialty Gas News.

giving us strong confidence that these plants will deliver commercial product for industries with urgent need, including next-generation semiconductors and healthcare.

The two divisions that represent the powerhouse of the Company responsible for the majority of our near to mid-term EBITDA targets, namely PET Labs and Renergen, are operating ahead of our internal expectations both in terms of timing and potential profitability, reinforcing our confidence in our 2031 EBITDA target of greater than $300 million.4 We are currently negotiating helium and hydrocarbon supply contracts with potential large global customers on 5-15 years “take-or-pay” arrangements, which gives us considerable visibility over our expected future revenues.

Additionally, during 2H 2026:

• Renergen, through the planned reverse merger between Noble Africa LLC and ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA”), is expected to become a Nasdaq-listed company upon the closing of the reverse merger, allowing investors to invest in a commercial helium-focused company. ASPI will initially own approximately 89% of the combined company, after giving effect to the private placement financing that is expected to close immediately prior to completion of the reverse merger.

• Quantum Leap Energy (QLE), our nuclear fuels subsidiary, continues to pursue a public listing as a separate company. Having raised substantial amounts of capital between 2023 and 2026, we believe that QLE is well funded through its current development program and is expected to continue its momentum towards additional milestones, including commercial production of nuclear fuels. Following the recent exchange of certain QLE convertible notes held by third party investors for ASPI common stock, we hope to support our position to make a potential future distribution of QLE common stock to ASPI’s shareholders as of a to-be-determined future record date in a tax efficient manner.5

• Alpa Theranostics is a wholly owned biotechnology company established to develop technology that we have been incubating within ASP Isotopes for the last 24 months. Alpa Theranostics is expected to advance its first clinical candidates into human clinical trials during the next 12 months. We have observed efficacy in pre-clinical trials using novel nanobodies, which will be conjugated to a radioisotope produced by PET Labs.

4 EBITDA is a non-GAAP financial measure and is defined as n